Patents Assigned to Amunix Operating, Inc.
  • XTEN conjugate compositions and methods of making same
    Patent number: 10172953
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: January 8, 2019
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
  • Blood glucose lowering compound
    Patent number: 10035839
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 31, 2018
    Assignees: Eli Lilly and Company, Amunix Operating Inc.
    Inventors: David Bruce Baldwin, John Michael Beals, Andrew Ihor Korytko, Bryant Rhodius McLaughlin, Volker Schellenberger
  • Glucose-regulating polypeptides and methods of making and using same
    Patent number: 10000543
    Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 19, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same
    Patent number: 9976166
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 22, 2018
    Assignee: AMUNIX OPERATING INC.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. C. Stemmer, Nathan C. Geething
  • Biologically active proteins having increased in vivo and/or in vitro stability
    Patent number: 9938331
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 10, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Nathaniel C. Gordon, Andreas Crameri, Mikhail Popkov
  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 9926351
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: March 27, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Growth hormone polypeptides and methods of making and using same
    Patent number: 9849188
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: December 26, 2017
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland, Benjamin Spink
  • Coagulation factor IX compositions and methods of making and using same
    Patent number: 9758776
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 12, 2017
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20170247676
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Application
    Filed: February 8, 2017
    Publication date: August 31, 2017
    Applicant: Amunix Operating Inc.
    Inventors: Volker SCHELLENBERGER, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • Glucose-regulating polypeptides and methods of making and using same
    Patent number: 9540430
    Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 10, 2017
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20160376344
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 29, 2016
    Applicant: Amunix Operating Inc.
    Inventors: Volker SCHELLENBERGER, Pei-Yun CHANG, Fatbardha VARFAJ, John KULMAN, Tongyao LIU, Garabet G. TOBY, Haiyan JIANG, Robert PETERS, Deping WANG, Baisong MEI, Joshua SILVERMAN, Chia-Wei WANG, Benjamin SPINK, Nathan GEETHING
  • COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20160362672
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 15, 2016
    Applicant: Amunix Operating Inc.
    Inventors: Volker SCHELLENBERGER, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • FACTOR VIII-XTEN FUSIONS AND USES THEREOF
    Publication number: 20160199454
    Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.
    Type: Application
    Filed: August 14, 2014
    Publication date: July 14, 2016
    Applicants: Biogen MA Inc., Amunix Operating Inc.
    Inventors: Tongyao LIU, Pei-Yun CHANG, John KULMAN, Volker SCHELLENBERGER, Haiyan JIANG, Robert T. PETERS, Ekta Seth CHHABRA
  • Coagulation factor IX compositions and methods of making and using same
    Patent number: 9376672
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 28, 2016
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 9371369
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: June 21, 2016
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20160137711
    Abstract: The present invention relates to compositions comprising GLP-2 protein or variants thereof linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of GLP-2-related conditions.
    Type: Application
    Filed: September 12, 2012
    Publication date: May 19, 2016
    Applicant: AMUNIX OPERATING INC.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Geething, Benjamin Spink
  • Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same
    Patent number: 9249211
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: February 2, 2016
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething
  • COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20150344862
    Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Application
    Filed: May 12, 2015
    Publication date: December 3, 2015
    Applicant: Amunix Operating Inc.
    Inventors: Volker SCHELLENBERGER, Willem P. Stemmer, Nathan C. Geething, Wayne To, Joshua Silverman, Chia-wei Wang, Benjamin Spink
  • Growth hormone polypeptides and methods of making and using same
    Patent number: 9168312
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: October 27, 2015
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland, Benjamin Spink
  • FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF
    Publication number: 20150266943
    Abstract: The present invention includes a chimeric protein comprising a VWF protein with D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain of a VWF fragment is associated with a FVIII polypeptide chain linked to an XTEN sequence. The VWF fragment polypeptide chain can prevent or inhibit binding of endogenous VWF to FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to FVIII protein, VWF fragment can extend half-life of chimeric protein comprising FVIII protein. The invention includes nucleotides, vectors, host cells, use of VWF fragment, or chimeric proteins.
    Type: Application
    Filed: July 10, 2013
    Publication date: September 24, 2015
    Applicants: AMUNIX OPERATING INC., BIOGEN MA INC.
    Inventors: Ekta Seth Chhabra, Tongyao Liu, Pei-yun Chang, Robert T. Peters, John Kulman